Rituximab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy

PHASE3CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

April 1, 2019

Primary Completion Date

May 30, 2023

Study Completion Date

November 30, 2023

Conditions
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Interventions
DRUG

Rituximab

Patients will receive two doses of rituximab 1 g at two-week interval and one dose of rituximab 1 g at month 6

OTHER

Placebo

Patients will receive two doses of placebo at two-week interval and one dose of placebo at month 6

Trial Locations (1)

Unknown

IRCCS Istituto Clinico Humanitas, Rozzano

All Listed Sponsors
collaborator

Ospedale Mondino di Pavia

UNKNOWN

collaborator

University of Turin, Italy

OTHER

collaborator

Istituto Neurologico Carlo Besta di Milano

UNKNOWN

collaborator

San Raffaele University Hospital, Italy

OTHER

collaborator

Università di Messina

UNKNOWN

collaborator

Universita degli Studi di Genova

OTHER

collaborator

Istituto Di Ricerche Farmacologiche Mario Negri

OTHER

collaborator

Università di Napoli Federico II

UNKNOWN

lead

Istituto Clinico Humanitas

OTHER

NCT06325943 - Rituximab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Biotech Hunter | Biotech Hunter